Clinical Trials on Advanced Neuroendocrine Carcinoma in Germany

Total 1917 results

AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
CellAct Pharma GmbH
Mundipharma-EDO GmbH

Terminated

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors (CAP7-1)

Advanced Endstage Solid Carcinomas in Adults

Germany
Karsten Gavenis

Recruiting

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma

Germany, Austria
Technische Universität Dresden
Roche Pharma AG

Recruiting

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE)

Large Cell Neuroendocrine Carcinoma of the Lung

Germany
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Advanced Melanoma

Germany
University of Regensburg
ClinAssess GmbH

Unknown

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Advanced Melanoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Bristol-Myers Squibb; Eisai GmbH

Completed

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany
Eanm Research Ltd

Withdrawn

Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma (SUMMIT)

Medullary Thyroid Carcinoma

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Genzyme, a Sanofi Company
Worldwide Clinical Trials

Completed

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

Symptomatic, Aggressive, Sporadic, Unresectable, Locally | Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Belgium, Italy, Netherlands, Spain, France, Germany, United Kingdom, Luxembourg
Novartis Pharmaceuticals

Completed

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Metastatic Melanoma and Merkel Cell Carcinoma

Germany, Switzerland
AIO-Studien-gGmbH
Servier

Completed

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma Advanced

Germany
Paola Anna Erba
Erasmus Medical Center; Jagiellonian University; Medical University Innsbruck; University... and other collaborators

Completed

Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC (GRAN-T-MTC)

Medullary Thyroid Carcinoma

Austria, Germany, Netherlands, Poland, Slovenia
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Philogen S.p.A.
Immatics Biotechnologies GmbH

Terminated

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma

Germany, Austria, Denmark, France, Spain, United Kingdom
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
SLK Kliniken Heilbronn GmbH

Recruiting

IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

Advanced Renal Cell Carcinoma

Germany
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
University Women's Hospital Tübingen

Completed

Electrochemotherapy for the Inoperable Vulva Carcinoma

Advanced Inoperable Vulva Carcinoma

Germany
University Hospital, Tours
European Academy of Dermatology and Venerology

Not yet recruiting

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines (SUMMERTIME)

Merkel Cell Carcinoma

United Kingdom, Austria, Finland, France, Germany, Italy, Netherlands, Romania, Sweden, Turkey
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Pancreatic Neoplasms | Neuroendocrine Tumor | Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States, Canada, Spain, Argentina, Germany, Belgium, Italy, France, Sweden, Australia, Netherlands
4SC AG

Completed

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE)

Advanced Colorectal Carcinoma

Germany
Prof. Dr. med. Dirk Schadendorf
Bristol-Myers Squibb

Active, not recruiting

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)

Merkel Cell Carcinoma

Germany, Netherlands
University of Erlangen-Nürnberg Medical School

Completed

Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Locally Advanced Head and Neck Squamous Cell Carcinoma

Germany
University Hospital Dresden

Completed

Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct

Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
University of Erlangen-Nürnberg Medical School

Not yet recruiting

Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region

Locally Advanced Salivary Gland Carcinoma

Germany
Genzyme, a Sanofi Company

Active, not recruiting

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)

Medullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid Cancer

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
AIO-Studien-gGmbH
Servier; Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest...

Active, not recruiting

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NIFE)

Biliary Tract Cancer | Extrahepatic Bile Duct Carcinoma | Non-Resectable Hepatocellular Carcinoma | Adenocarcinoma Metastatic | Adenocarcinoma of the Biliary Tract | Adenocarinoma Locally Advanced | Intrahepatic Bile Duct Carcinoma

Germany
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Carcinoid Syndrome

Germany, United Kingdom
Institut für Klinische Krebsforschung IKF GmbH...

Terminated

CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Advanced Renal Cell Carcinoma (All Subtypes) | Metastatic Renal Cell Carcinoma (All Subtypes)

Germany
Interessenverband zur Qualitätssicherung der Arbeit...
OnkoDataMed GmbH

Terminated

Optimizing Pazopanib Exposure in RCC Patients (OPERA)

Metastatic Renal Cell Carcinoma | Locally Advanced Renal Cell Carcinoma

Germany
Bristol-Myers Squibb

Withdrawn

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Melanoma | Urothelial Carcinoma

Germany, Spain
Grupo Espanol de Tumores Neuroendocrinos
Pfizer

Active, not recruiting

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Neuroendocrine Tumors | Advanced Cancer

Spain, Germany, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Azienda Ospedaliera di Perugia

Not yet recruiting

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients (MELCAYA)

Advanced Melanoma | Early Melanoma

Italy, Sweden, France, Germany, Netherlands, Poland, Spain
CNAO National Center of Oncological Hadrontherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Fondazione IRCCS... and other collaborators

Recruiting

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC)

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma

Italy, Germany
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
iOMEDICO AG
Novartis Pharmaceuticals

Completed

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (FLIPPER)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell Carcinoma

Germany
GERCOR - Multidisciplinary Oncology Cooperative...
AstraZeneca

Active, not recruiting

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. (IMMUNO-BIL)

Advanced Biliary Tract Carcinoma

France
University Hospital Heidelberg
Heidelberg University; University of Jena; Martin-Luther-Universität Halle-Wittenberg and other collaborators

Recruiting

Decision Aid to Support Advanced Cancer Patients (PETUPAL)

Advanced Cancer

Germany
Krankenhaus Nordwest

Completed

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111)

Advanced Gastric Cancer | Esophagogastric Junction Cancer

Germany
Silence Therapeutics GmbH

Completed

Study With Atu027 in Patients With Advanced Solid Cancer

Advanced Solid Tumors

Germany
Novartis Pharmaceuticals

Completed

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Advanced or Metastatic Pancreatic Adenocarcinoma

Germany
University Hospital Tuebingen

Recruiting

Molecular Tumor Board at the Center for Personalized Medicine Tübingen (MTB@ZPM)

Advanced Cancer

Germany

Clinical Trials on Advanced Neuroendocrine Carcinoma in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations